{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:15:48Z","timestamp":1794431748379,"version":"4.9.1"},"reference-count":40,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 HL114589"],"award-info":[{"award-number":["U01 HL114589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR00042"],"award-info":[{"award-number":["UL1 TR00042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 HL119073"],"award-info":[{"award-number":["UM1 HL119073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB17A0"],"award-info":[{"award-number":["MUHLEB17A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,8,15]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Early eradication of methicillin-resistant<jats:italic>Staphylococcus aureus<\/jats:italic>(MRSA) in cystic fibrosis is desirable. Prospective studies are challenging owing to the feasibility of recruiting patients with a rare event in an orphan disease. Our prior randomised study (<jats:italic>Staph Aureus<\/jats:italic>Resistance-Treat Or Observe (STAR-too)) showed improved clearance and outcomes with aggressive therapy compared to no treatment. We present a novel trial design to guide treatment for eradicating incident infection with a focus on feasibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Subjects with cystic fibrosis with incident MRSA infection were enrolled into the<jats:italic>Staph Aureus<\/jats:italic>Resistance-Treat Early And Repeat (STAR-ter) protocol and treated with a combination of an oral antibiotic and topical (nare and throat) decolonisation. The primary outcome was MRSA-negative respiratory culture at Day 28,<jats:italic>i.e.<\/jats:italic>14\u2005days after completion of oral antibiotics. What was novel about this study design was that the control\/comparator group was the untreated group of the STAR-too trial. This design was developed because having a \u201cno treatment\u201d group would be unethical given prior findings and a superiority design would delay the time to results based on small numbers of eligible subjects. Both studies used the same inclusion and exclusion criteria and drew subjects from the same geographic regions. The main difference between the studies was the use of a single oral antibiotic, trimethoprim-sulfamethoxazole, rather than the combination with oral rifampin used in STAR-too.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>An innovative approach to address a clinical question for a rare event in an orphan disease, cystic fibrosis, is presented to enhance current clinical evidence to guide cystic fibrosis care in relation to new MRSA infection.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00190-2022","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:18:09Z","timestamp":1665069489000},"page":"00190-2022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Eradication of early MRSA infection in cystic fibrosis: a novel study design for the STAR-ter trial"],"prefix":"10.1183","volume":"8","author":[{"given":"Fiona","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-1598","authenticated-orcid":false,"given":"Marianne S.","family":"Muhlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"2024101711405751000_8.4.00190-2022.1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-781OC"},{"key":"2024101711405751000_8.4.00190-2022.2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0039-1698464","article-title":"Microbiology of cystic fibrosis airway disease","volume":"40","author":"Blanchard","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"2024101711405751000_8.4.00190-2022.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.791"},{"key":"2024101711405751000_8.4.00190-2022.4","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20604"},{"key":"2024101711405751000_8.4.00190-2022.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1421OC"},{"key":"2024101711405751000_8.4.00190-2022.6","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20914"},{"key":"2024101711405751000_8.4.00190-2022.7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcf.2011.02.004","article-title":"Treatment intensity and characteristics of MRSA infection in CF","volume":"10","author":"Muhlebach","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2024101711405751000_8.4.00190-2022.8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6809e1"},{"key":"2024101711405751000_8.4.00190-2022.9","unstructured":"Cystic Fibrosis Foundation . Cystic Fibrosis Foundation Patient Registry. Bethesda, MD, Cystic Fibrosis Foundation, 2018. www.cff.org\/medical-professionals\/patient-registry"},{"key":"2024101711405751000_8.4.00190-2022.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201207-1160OE"},{"key":"2024101711405751000_8.4.00190-2022.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.04.009"},{"key":"2024101711405751000_8.4.00190-2022.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2003.12.003"},{"key":"2024101711405751000_8.4.00190-2022.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2006.10.011"},{"key":"2024101711405751000_8.4.00190-2022.14","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208949"},{"key":"2024101711405751000_8.4.00190-2022.15","doi-asserted-by":"crossref","first-page":"e0213497","DOI":"10.1371\/journal.pone.0213497","article-title":"Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: a randomized multicenter study","volume":"14","author":"Dolce","year":"2019","journal-title":"PLoS One"},{"key":"2024101711405751000_8.4.00190-2022.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08277-6"},{"key":"2024101711405751000_8.4.00190-2022.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2024"},{"key":"2024101711405751000_8.4.00190-2022.18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40264-020-00944-1","article-title":"A framework for methodological choice and evidence assessment for studies using external comparators from real-world data","volume":"43","author":"Gray","year":"2020","journal-title":"Drug Saf"},{"key":"2024101711405751000_8.4.00190-2022.19","doi-asserted-by":"crossref","first-page":"e186014","DOI":"10.1001\/jamanetworkopen.2018.6014","article-title":"How routinely collected data for randomized trials provide long-term randomized real-world evidence","volume":"1","author":"Hemkens","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2024101711405751000_8.4.00190-2022.20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrd.2017.151","article-title":"Flexibility in the FDA approach to orphan drug development","volume":"16","author":"Hunter","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2024101711405751000_8.4.00190-2022.21","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research . Guidance for Industry: E 10 Choice of Control Group and Related Issues in Clinical Trials. Rockville, MD, Food and Drug Administration, 2001."},{"key":"2024101711405751000_8.4.00190-2022.22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(82)90024-1"},{"key":"2024101711405751000_8.4.00190-2022.23","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22815"},{"key":"2024101711405751000_8.4.00190-2022.24","first-page":"73","article-title":"Pharmacokinetics of trimethoprim-sulfamethoxazole in children","volume":"112","author":"Wilfert","year":"1975","journal-title":"Can Med Assoc J"},{"key":"2024101711405751000_8.4.00190-2022.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)81019-7"},{"key":"2024101711405751000_8.4.00190-2022.26","first-page":"735","article-title":"Oral rifampin and trimethoprim\/sulfamethoxazole therapy in asymptomatic carriers of methicillin-resistant Staphylococcus aureus infections","volume":"140","author":"Ellison","year":"1984","journal-title":"West J Med"},{"key":"2024101711405751000_8.4.00190-2022.27","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00255-09"},{"key":"2024101711405751000_8.4.00190-2022.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409083311003"},{"key":"2024101711405751000_8.4.00190-2022.29","unstructured":"Common Terminology Criteria For Adverse Events (CTCAE): version 4.0. Washington, DC, US Department of Health and Human Services, 2009."},{"key":"2024101711405751000_8.4.00190-2022.30","first-page":"CD009650","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","volume":"2","author":"Lo","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101711405751000_8.4.00190-2022.31","first-page":"CD009650","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","volume":"7","author":"Lo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101711405751000_8.4.00190-2022.32","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201402-050AS"},{"key":"2024101711405751000_8.4.00190-2022.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.06.002"},{"key":"2024101711405751000_8.4.00190-2022.34","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23132"},{"key":"2024101711405751000_8.4.00190-2022.35","doi-asserted-by":"crossref","first-page":"e1002966","DOI":"10.1371\/journal.pmed.1002966","article-title":"Noncompletion and nonpublication of trials studying rare diseases: a cross-sectional analysis","volume":"16","author":"Rees","year":"2019","journal-title":"PLoS Med"},{"key":"2024101711405751000_8.4.00190-2022.36","unstructured":"US Food and DrugAdministration . Complex Innovative Trial Designs Pilot Program . 2019. www.fda.gov\/drugs\/development-resources\/complex-innovative-trial-design-meeting-program Date last accessed: March 2022."},{"key":"2024101711405751000_8.4.00190-2022.37","unstructured":"European Medicines Agency . EMA Regulatory Science to 2025. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf Date last accessed: March 30, 2022."},{"key":"2024101711405751000_8.4.00190-2022.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024101711405751000_8.4.00190-2022.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024101711405751000_8.4.00190-2022.40","doi-asserted-by":"crossref","first-page":"e0314821","DOI":"10.1128\/mbio.03148-21","article-title":"Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00190-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:21:12Z","timestamp":1740374472000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00190-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,5]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1183\/23120541.00190-2022"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00190-2022","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}